Ascendiant Capital maintains Plus Therapeutics at 'buy' with a price target of $26.00

  • Investing.com
Ascendiant Capital maintains Plus Therapeutics at 'buy' with a price target of $26.00

An analyst from Ascendiant Capital maintained Plus Therapeutics (NASDAQ: PSTV ) at 'buy' with a price target of $26.00 from a prior price target of $30.00.

Prior to this rating, Plus Therapeutics had 4 buy ratings, 0 hold ratings, and 0 sell ratings.

For consensus analyst estimates and price targets on Plus Therapeutics, click here. For more news on Plus Therapeutics, click here.

Plus Therapeutics's stock price closed at $2.820. They are up 6.82% in the last month and down -75.120% in the last 12 months.

According to Investing Pro, Plus Therapeutics's fair value is $3.783, an upside of 34.134%. Plus Therapeutics's fair value comes with a high degree of uncertainty, according to InvestingPro.

Check out Plus Therapeutics's recent earnings performance and financials here.

Drop an image here or Supported formats: *.jpg, *.png, *.gif up to 5mb

Error: File type not supported

Drop an image here or

100